Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study. Issue 10291 (12th June 2021)

• Record Type: Journal Article
• Authors: Pylypchuk, Romana; Wells, Sue; Kerr, Andrew; Poppe, Katrina; Harwood, Matire; Mehta, Suneela; Grey, Corina; Wu, Billy P; Selak, Vanessa; Drury, Paul L; Chan, Wing Cheuk; Orr-Walker, Brandon; Murphy, Rinki; Mann, Jim; Krebs, Jeremy D; Zhao, Jinfeng; Jackson, Rod
• Is Part Of: Lancet. Volume 397:Issue 10291(2021)
• Page Start: 2264
• Page End: 2274
• Publication Date: 2021-06-12
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Medicine; Electronic journals; Periodicals; 610.5
• DOI: 10.1016/S0140-6736(21)00572-9
• Languages: English
• ISSNs: 0140-6736

Abstract

Summary: Background: Until recently, most patients with diabetes worldwide have been diagnosed when symptomatic and have high cardiovascular risk, meaning most should be prescribed cardiovascular preventive medications. However, in New Zealand, a world-first national programme led to approximately 90% of eligible adults being screened for diabetes by 2016, up from 50% in 2012, identifying many asymptomatic patients with recent-onset diabetes. We hypothesised that cardiovascular risk prediction equations derived before widespread screening would now significantly overestimate risk in screen-detected patients. Methods: New Zealanders aged 30–74 years with type 2 diabetes and without known cardiovascular disease, heart failure, or substantial renal impairment were identified from the 400 000-person PREDICT primary care cohort study between Oct 27, 2004, and Dec 30, 2016, covering the period before and after widespread screening. Sex-specific equations estimating 5-year risk of cardiovascular disease were developed using Cox regression models, with 18 prespecified predictors, including diabetes-related and renal function measures. Equation performance was compared with an equivalent equation derived in the New Zealand Diabetes Cohort Study (NZDCS), which recruited between 2000 and 2006, before widespread screening. Findings: 46 652 participants were included in the PREDICT-1° Diabetes subcohort, of whom 4114 experienced first cardiovascular events during follow-up (median 5·2 years, IQR 3·3–7·4). 14 829 (31·8%) were not taking oral hypoglycaemic medications or insulin at baseline. Median 5-year cardiovascular risk estimated by the new equations was 4·0% (IQR 2·3–6·8) in women and 7·1% (4·5–11·2) in men. The older NZDCS equation overestimated median cardiovascular risk by three times in women (median 14·2% [9·7–20·0]) and two times in men (17·1% [4·5–20·0]). Model and discrimination performance measures for PREDICT-1° Diabetse equations were also significantly better than for the NZDCS equation (eg, for women: R 2 =32% [95% CI 29–34], Harrell's C =0·73 [0·72–0·74], Royston's D =1·410 [1·330–1·490] vs R 2 =24% [21–26], C =0·69 [0·67–0·70], and D =1·147 [1·107–1·187]). Interpretation: International treatment guidelines still consider most people with diabetes to be at high cardiovascular risk; however, we show that recent widespread diabetes screening has radically changed the cardiovascular risk profile of people with diabetes in New Zealand. Many of these patients have normal renal function, are not dispensed glucose-lowering medications, and have low cardiovascular risk. These findings have clear international implications as increased diabetes screening is inevitable due to increasing obesity, simpler screening tests, and the introduction of new-generation glucose-lowering medications that prevent cardiovascular events. Cardiovascular risk prediction equations derived from contemporary diabetes populations, with multiple diabetes-related and renal function predictors, will be required to better differentiate between low-risk and high-risk patients in this increasingly heterogeneous population and to inform appropriate non-pharmacological management and cost-effective targeting of expensive new medications. Funding: Health Research Council of New Zealand, Heart Foundation of New Zealand, and Healthier Lives National Science Challenge.